Copyright
©The Author(s) 2024.
世界华人消化杂志. 2024-06-28; 32(6): 405-411
在线出版 2024-06-28. doi: 10.11569/wcjd.v32.i6.405
在线出版 2024-06-28. doi: 10.11569/wcjd.v32.i6.405
肿瘤类型 | 表达水平 | 致癌/抑癌基因 | 功能作用 | miRNAs | 目标基因 | 参考文献 |
GC | Up-regulated | Oncogene | Proliferation, migration, invasion, apoptosis | / | / | [7] |
GC | Up-regulated | Oncogene | Proliferation, invasionability, apoptosis | miR-135a-5p | JAK2/STAT3 | [8] |
GC | Up-regulated | Oncogene | Mediating 5-fu resistance | miR-506-3p | PTBP1 | [9] |
GC | Up-regulated | Oncogene | EMT, invasion | / | DKK3 | [10] |
GC | Up-regulated | Oncogene | Proliferation, apoptosis, migration, invasion | / | P53, c-Myc | [11] |
CRC | Up-regulated | Oncogene | Migration, apoptosis | / | ASCL2, ETS2, c-Myc | [13] |
CRC | Up-regulated | Oncogene | Proliferation, migration | miR-200a-3p | / | [14] |
Colon cancer | Up-regulated | Oncogene | Proliferation | miR-302a-3p | AKT | [15] |
CRC | Up-regulated | Oncogene | Proliferation, migration, invasion, apoptosis | miR-132-3p | USP22 | [16] |
CRC | Up-regulated | Oncogene | Proliferation, apoptosis | miR-214-3p | ABCB1 | [17] |
CRC | Up-regulated | Oncogene | Proliferation, migration, invasion, EMT | miR-124-3p | MCP-1 | [18] |
CRC | Up-regulated | Oncogene | Proliferation, migration, invasion, EMT | miR-195-5p | YAP1/TEAD1 | [19] |
ESCC | Up-regulated | Oncogene | Proliferation, invasion, apoptosis | / | c-myc, cyclin | [21] |
ESCC | Up-regulated | Oncogene | Proliferation, migration, apoptosis, EMT | miR-140-5p | ZEB1 | [22] |
EC | Up-regulated | Oncogene | Proliferation | miR-802 | PTCH1 | [23] |
ESCC | Up-regulated | Oncogene | Proliferation, migration | / | EIF4A3/RhoU | [24] |
PC | Up-regulated | Oncogene | Proliferation, migration, invasion, apoptosis | miR-302b-3p | SLC2A4 | [26] |
PC | Up-regulated | Oncogene | Proliferation, migration, invasion, lipogenesis | miR-195 | SREBP2 | [27] |
CCA | Up-regulated | Oncogene | Proliferation, apoptosis | miR-146a-5p | GATA6 | [29] |
HCC | Up-regulated | Oncogene | Proliferation, migration, invasion | / | / | [31] |
HCC | Up-regulated | Oncogene | Proliferation, migration, invasion, apoptosis | miR-17-5p | P62 | [32] |
HCC | Up-regulated | Oncogene | Invasiveness, proliferation | / | / | [33] |
HCC | Up-regulated | Oncogene | Proliferation, migration, invasion | miR-186 | / | [34] |
HCC | Up-regulated | Oncogene | Proliferation, invasion tumorigenesis | miR-195 | / | [35] |
HCC | Up-regulated | Oncogene | Proliferation, migration, invasion, apoptosis and EMT | miR-4500 | STAT3 | [36] |
HCC | Up-regulated | Oncogene | Proliferation | miR-302a-3p | FGF19 | [37] |
HCC | Up-regulated | Oncogene | Metastasis, EMT | miR-605-3p | TRAF6、NF-κB | [38] |
HCC | Up-regulated | Oncogene | Viability, apoptosis | miR-23b-3p | EGR1 | [39] |
HCC | Up-regulated | Oncogene | Proliferation, migration, invasion, EMT, apoptosis | let-7b-5p | CDC25B、HMGA2 | [41] |
HCC | Up-regulated | Oncogene | Angiogenesis | miR-4500 | GALNT1、PI3K/Akt/mTOR | [43] |
HCC | Up-regulated | Oncogene | Metastasis | miR 942 3p | MMP9 | [44] |
HCC | Down-regulated | Tumor suppressor | Proliferation, chemoresistance, tumorigenicity | hsa-miR-93 | / | [45] |
肿瘤类型 | 临床特征 | 参考文献 |
GC | Invasion depth, lymph node metastasis, TNM stage, histological differentiation | [7] |
GC | Tumor size, TNM stage, poor survival | [8] |
GC | Invasion depth | [11] |
CRC | TNM stage | [13] |
CRC | Metastasis, lymph node | [14] |
CRC | LV1, PNI, TNM stage, lymph node, metastasis, distant metastasis, poor prognosis | [19] |
ESCC | Tumor stage, lymph nodes metastasis, clinical stage, poor survival, poor prognosis | [21] |
ESCC | Tumour differentiation, T stage | [24] |
PC | Poor prognosis | [26] |
PC | Gemcitabine resistance | [28] |
HCC | Tumor size, AFP level, PVTT, metastasis, poor survival, sorafenib resistance | [31] |
HCC | Multiple tumors, macrovascular invasion, poor prognosis | [32] |
HCC | Serum AFP level, poor prognosis | [33] |
HCC | Tumor size, TNM stage, ALT level, HBV DNA level | [34] |
HCC | Tumor size, lymph node status, TNM stage and poor prognosis | [36] |
HCC | Poor prognosis | [37] |
HCC | Tumour diameter, tumour thrombus, tumour satellites, poor prognosis | [38] |
HCC | Sorafenib resistance | [39] |
HCC | Tumor size, TNM stage, vascular invasion, sorafenib resistance | [40] |
HCC | Poor prognosis | [44] |
引文著录: 叶惠, 李明月, 施瑞华. 长链非编码RNA SNHG16在消化系统肿瘤中作用机制研究进展. 世界华人消化杂志 2024; 32(6): 405-411